Literature DB >> 7617521

Transepithelial transport properties of peptidomimetic thrombin inhibitors in monolayers of a human intestinal cell line (Caco-2) and their correlation to in vivo data.

E Walter1, T Kissel, M Reers, G Dickneite, D Hoffmann, W Stüber.   

Abstract

Peptidomimetic thrombin inhibitors (TI), derived from L-Asp-D-Phe were examined in confluent monolayers of a human colon carcinoma cell line (Caco-2) to elucidate their transepithelial transport properties. Effect availabilities, based on activated partial thromboplastin time (aPTT) measurements in rats, after peroral administration of five TI correlated reasonably well with permeability coefficients obtained from in vitro transport studies in Caco-2 monolayers, whereas physicochemical properties, such as molecular mass, solubilities, pKa and octanol-buffer partition coefficients failed to yield meaningful relationships. Substitution of the beta-carboxylic group of L-Asp leads to analogues which are mainly transported by passive diffusion, while an unsubstituted carboxylic group favours carrier-mediated active transport. The effects of concentration, temperature, competitive inhibitors and direction dependence on in vitro transport were investigated. The results obtained are compatible with a saturable carrier-mediated transport, operating parallel to a passive paracellular route. The Michaelis-Menten parameters for the active transport component (Km = 1.67 mM, Vmax = 26.5 pmol min-1 mg protein-1) indicate an involvement of the intestinal di/tripeptide transport system for one of the TI. The Caco-2 transport model may be helpful for the design of perorally active peptidomimetics.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7617521     DOI: 10.1023/a:1016244316584

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  17 in total

1.  Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa.

Authors:  A R Hilgers; R A Conradi; P S Burton
Journal:  Pharm Res       Date:  1990-09       Impact factor: 4.200

2.  In vitro drug absorption models. I. Brush border membrane vesicles, isolated mucosal cells and everted intestinal rings: characterization and salicylate accumulation.

Authors:  I Osiecka; P A Porter; R T Borchardt; J A Fix; C R Gardner
Journal:  Pharm Res       Date:  1985-11       Impact factor: 4.200

3.  Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco-2.

Authors:  A H Dantzig; L Bergin
Journal:  Biochim Biophys Acta       Date:  1990-09-07

4.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells.

Authors:  P Artursson; J Karlsson
Journal:  Biochem Biophys Res Commun       Date:  1991-03-29       Impact factor: 3.575

5.  Transepithelial transport of oral cephalosporins by monolayers of intestinal epithelial cell line Caco-2: specific transport systems in apical and basolateral membranes.

Authors:  K Inui; M Yamamoto; H Saito
Journal:  J Pharmacol Exp Ther       Date:  1992-04       Impact factor: 4.030

6.  Transepithelial transport and metabolism of thyrotropin-releasing hormone (TRH) in monolayers of a human intestinal cell line (Caco-2): evidence for an active transport component?

Authors:  E Walter; T Kissel
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

7.  Intestinal absorption mechanisms of thyrotropin-releasing hormone.

Authors:  S Yokohama; T Yoshioka; K Yamashita; N Kitamori
Journal:  J Pharmacobiodyn       Date:  1984-07

8.  Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells.

Authors:  P Artursson
Journal:  J Pharm Sci       Date:  1990-06       Impact factor: 3.534

9.  Common characteristics for Na+-dependent sugar transport in Caco-2 cells and human fetal colon.

Authors:  A Blais; P Bissonnette; A Berteloot
Journal:  J Membr Biol       Date:  1987       Impact factor: 1.843

10.  In Vitro Drug Absorption Models. II. Salicylate, Cefoxitin, α-Methyldopa and Theophylline Uptake in Cells and Rings: Correlation with In Vivo Bioavailability.

Authors:  P A Porter; I Osiecka; R T Borchardt; J A Fix; L Frost; C Gardner
Journal:  Pharm Res       Date:  1985-11       Impact factor: 4.200

View more
  7 in total

Review 1.  Intestinal peptide transport systems and oral drug availability.

Authors:  C Y Yang; A H Dantzig; C Pidgeon
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

Review 2.  Carrier-mediated intestinal transport of drugs.

Authors:  A Tsuji; I Tamai
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

3.  Prodrug approach for alphaIIbbeta3-peptidomimetic antagonists to enhance their transport in monolayers of a human intestinal cell line (Caco-2): comparison of in vitro and in vivo data.

Authors:  W Kamm; P Raddatz; J Gante; T Kissel
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

4.  Effects of permeation enhancers on the transport of a peptidomimetic thrombin inhibitor (CRC 220) in a human intestinal cell line (Caco-2).

Authors:  U Werner; T Kissel; M Reers
Journal:  Pharm Res       Date:  1996-08       Impact factor: 4.200

5.  Transport of peptidomimetic thrombin inhibitors with a 3-amidino-phenylalanine structure: permeability and efflux mechanism in monolayers of a human intestinal cell line (Caco-2).

Authors:  W Kamm; J Hauptmann; I Behrens; J Stürzebecher; F Dullweber; H Gohlke; M Stubbs; G Klebe; T Kissel
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

Review 6.  Oral Contraceptives after Bariatric Surgery.

Authors:  Joël Schlatter
Journal:  Obes Facts       Date:  2017-04-22       Impact factor: 3.942

7.  The effect of cephalexin in influencing the pharmacokinetics of a novel drug - 5'-valyl-cytarabine hydrochloride.

Authors:  Xiaotong Song; Yinghua Sun; Chenyao Zhao; Zhonggui He
Journal:  Asian J Pharm Sci       Date:  2016-08-31       Impact factor: 6.598

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.